This study is currently not recruiting participants.

An Open-label Study Investigating the Safety and Efficacy of rhPTH (1-84) in Subjects with Hypoparathyroidism

Study on the Safety and Efficacy of an Investigational Medication for Previous Participants

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

This study is designed to evaluate the safety and efficacy of 52 weeks of once-daily subcutaneous injections of rhPTH (1-84) for subjects who have previously been exposed to rhPTH (1-84) in the SHP634-101 (IRB 1701082476).

Detailed description of study

This study is designed to evaluate the safety and efficacy of 52 weeks of once-daily subcutaneous injections of rhPTH (1-84) for subjects who have previously been exposed to rhPTH (1-84) in the SHP634-101 (IRB 1701082476).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: hypoparathyroidism
  • Age: 100 years or below
  • Gender: All

This study investigates the safety and effectiveness of a once-daily injection given under the skin for 52 weeks. The injection is an investigational medication, which means it is still being studied. It is intended for individuals who have already received this medication in an earlier study.

Participants in this study will receive daily injections of the investigational medication for one year. The study aims to monitor the effects and any side effects that may occur during this period.

  • Who can participate: The study is open to individuals aged 18 and older who have previously participated in the SHP634-101 study and received the investigational medication.
  • Study details: The study will monitor the effects and any side effects of the investigational medication administered daily.
  • Study Timelines: The study will last 52 weeks.
Updated on 19 Feb 2024. Study ID: 1804179864

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team